TBPH
Theravance Biopharma Inc
17.10$
+0.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.7% | 11.1% | 5.9% | 39.2% | 1.2% | 298.6% | 363.2% | 350.1% | 123.5% | 70.7% | 58.5% | 5.1% | |
| 65.3% | 88.9% | 94.1% | 60.8% | 98.8% | 100.0% | 100.0% | -250.1% | -23.5% | 29.3% | 41.5% | 94.9% | |
| 1,441.8% | 306.6% | 291.3% | 1,130.2% | 333.5% | 298.6% | 363.2% | 364.4% | 136.5% | 80.7% | 59.1% | 34.8% | |
| 613.0% | 214.1% | 173.7% | 621.3% | 160.8% | 144.5% | 151.2% | 179.5% | 115.0% | 113.8% | 100.8% | 68.5% | |
| 2,054.8% | 520.7% | 465.0% | 1,751.5% | 494.3% | 443.1% | 514.2% | 215.9% | 155.6% | 126.8% | 114.5% | 107.2% | |
| -1,989.6% | -431.8% | -371.0% | -1,690.6% | -395.5% | -343.1% | -414.2% | -466.1% | -179.1% | -97.6% | -72.9% | -12.3% | |
| 16.0% | 1.5% | 2.9% | 55.6% | 17.4% | 43.4% | 11.9% | 15.5% | 12.4% | 4.1% | 4.0% | 2.3% | |
| -1,973.6% | -430.3% | -371.2% | -1,766.0% | -374.5% | -329.2% | -422.1% | -479.5% | -180.8% | -85.8% | -69.3% | 120.3% | |
| 54.4% | 2.3% | 20.8% | 89.0% | -17.5% | -7.1% | -11.9% | -0.3% | 0.0% | 10.3% | 18.3% | 21.7% | |
| -2,028.0% | -432.6% | -391.9% | -1,855.0% | -357.0% | -322.1% | -386.9% | -360.6% | 1,698.5% | -96.1% | -87.6% | 98.5% | |
| -1,966.8% | -424.4% | -361.9% | -1,684.2% | -351.9% | -277.3% | -400.6% | -420.9% | -148.2% | -89.9% | -59.7% | 127.7% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.